CRI
Carter's, Inc.
CRI has the edge over TSLA overall, supported by stronger valuation and stronger fundamentals.
TSLA
Tesla, Inc.
TSLA's outlook is improving, though it still trails on the overall score.
CRI Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Strong | |
| Healthy | |
| Strong |
CRI's profitability, cash flow and balance sheet are currently healthy, and its revenue is stable.
TSLA Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Stable | |
| Under pressure | |
| Strong |
TSLA's revenue and balance sheet are currently healthy, and its profitability is stable, but its cash flow is under pressure.
CRI PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 5.6x | $33.87 | — |
| Cheap | 8.6x | $51.89 | +53% |
| Forward | 10x | $33.87 | — |
| Fair | 12x | $74.79 | +121% |
| Expensive | 18x | $107 | +215% |
Historical ranges are pointers, not guarantees.
CRI has the edge over TSLA in the historical PE scenario, which offers more potential upside but is not a forecast.
TSLA PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 60x | $54.70 | -86% |
| Fair | 174x | $158 | -60% |
| Forward | 196x | $397 | — |
| Expensive | 415x | $378 | -4.9% |
| Current | 437x | $397 | — |
Historical ranges are pointers, not guarantees.
TSLA's PE is in its expensive range at 437x. If earnings grow as analysts expect, today's price would be 196x next year's earnings, in its fair range.
CRI Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Growth | |
| Stable | |
| Improving | |
| Limited | |
| Moderate |
Analysts expect CRI's earnings to grow and its profitability to improve, with its revenue holding steady.
TSLA Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect earnings and revenue growth for TSLA, with profitability holding steady. However, they disagree widely on these estimates.
CRI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $3.24 | -46% |
| Q3 2026 | $6.03 | +145% |
| Q2 2026 | $5.35 | +42% |
| Q1 2026 | $2.49 | -45% |
| Q4 2025 | $2.53 | -51% |
| Q3 2025 | $2.46 | -61% |
| Q2 2025 | $3.76 | -42% |
| Q1 2025 | $4.51 | -29% |
| Q4 2024 | $5.12 | -18% |
CRI has the edge over TSLA on earnings, with more consistent year-over-year improvement.
TSLA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.03 | +123% |
| Q3 2026 | $0.91 | -39% |
| Q2 2026 | $1.08 | -38% |
| Q1 2026 | $1.09 | -40% |
| Q4 2025 | $1.08 | -47% |
| Q3 2025 | $1.50 | -59% |
| Q2 2025 | $1.73 | -51% |
| Q1 2025 | $1.82 | -53% |
| Q4 2024 | $2.04 | -53% |
TSLA's earnings per share have fallen from their peak: $0.91 over the past year, against $4.30 in late 2023.
CRI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $752.5M | -0.7% |
| Q2 2026 | $615.5M | +5.2% |
| Q1 2026 | $681.1M | +8.1% |
| Q4 2025 | $925.5M | +7.6% |
| Q3 2025 | $757.8M | -0.1% |
| Q2 2025 | $585.3M | +3.7% |
| Q1 2025 | $629.8M | -4.8% |
| Q4 2024 | $859.7M | +0.2% |
CRI has the edge over TSLA on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 7.4% | +3.6 points |
| Q2 2026 | 23% | +22 points |
| Q1 2026 | 4.2% | 0 points |
| Q4 2025 | 9.2% | -0.5 points |
| Q3 2025 | 3.8% | -6.3 points |
| Q2 2025 | 0.7% | -6.3 points |
| Q1 2025 | 4.1% | -4.2 points |
| Q4 2024 | 9.7% | -6.2 points |
CRI has the edge over TSLA on profitability, with a higher operating margin.
TSLA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $28B | -0.2% |
| Q2 2026 | $28.2B | +26% |
| Q1 2026 | $22.4B | +16% |
| Q4 2025 | $24.9B | -3.1% |
| Q3 2025 | $28.1B | +12% |
| Q2 2025 | $22.5B | -12% |
| Q1 2025 | $19.3B | -9.2% |
| Q4 2024 | $25.7B | +2.1% |
TSLA's revenue has picked up after two years of holding roughly level: $28B last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 2.6% | -3.2 points |
| Q2 2026 | 1.4% | -2.7 points |
| Q1 2026 | 4.2% | +2.1 points |
| Q4 2025 | 5.7% | -0.5 points |
| Q3 2025 | 5.8% | -5 points |
| Q2 2025 | 4.1% | -2.2 points |
| Q1 2025 | 2.1% | -3.4 points |
| Q4 2024 | 6.2% | -2 points |
TSLA's operating margin was 2.6% last quarter, down 3.2 points from the same quarter a year ago, near the bottom of its range since 2019.
CRI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$117.4M | +$26.7M |
| Q2 2026 | $190M | +688% |
| Q1 2026 | -$543K | +$58.4M |
| Q4 2025 | $247.6M | -8.6% |
| Q3 2025 | -$144.1M | -$48.4M |
| Q2 2025 | $24.1M | -77% |
| Q1 2025 | -$59M | -$21.4M |
| Q4 2024 | $270.9M | -11% |
CRI usually generates cash, though not every quarter: the latest was −$117M, but it generated $320M over the past year.
TSLA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $1.5B | -62% |
| Q2 2026 | -$1.1B | -848% |
| Q1 2026 | $1.4B | +117% |
| Q4 2025 | $1.4B | -30% |
| Q3 2025 | $4B | +46% |
| Q2 2025 | $146M | -89% |
| Q1 2025 | $664M | +$3.2B |
| Q4 2024 | $2B | -1.6% |
TSLA still generates free cash flow, though less than at its 2025 peak: $3.3B over the past year.
CRI Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +36.1K shares |
| 1 year | +0.5% | +192K shares |
| 3 years | -2.2% | -806K shares |
| 5 years | -18% | -7.8M shares |
| Available history | -20% | -9.1M shares |
CRI has 36M diluted shares, up 0.5% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | $16.7M |
| Q2 2024 | $24.8M |
| Q1 2024 | $9M |
TSLA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | +1M shares |
| 1 year | +0.4% | +15M shares |
| 3 years | +1.4% | +48M shares |
| 5 years | +5.1% | +172M shares |
| Available history | +33% | +886M shares |
TSLA has the edge over CRI on shareholder dilution, with a more favorable share count trend.
CRI Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.3x | Very low |
| Q2 2026 | -0.3x | Net Cash |
| Q1 2026 | 0.5x | Very low |
| Q4 2025 | 0.4x | Very low |
| Q3 2025 | 1.6x | Healthy |
| Q2 2025 | 0.7x | Very low |
| Q1 2025 | 0.6x | Very low |
| Q4 2024 | 0.3x | Very low |
CRI's net debt is less than a year of its operating earnings (EBITDA), down from 1.6 years a year ago.
TSLA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -1.1x | Net Cash |
| Q2 2026 | -0.8x | Net Cash |
| Q1 2026 | -0.9x | Net Cash |
| Q4 2025 | -1.1x | Net Cash |
| Q3 2025 | -1.4x | Net Cash |
| Q2 2025 | -1.1x | Net Cash |
| Q1 2025 | -1.1x | Net Cash |
| Q4 2024 | -1.0x | Net Cash |
TSLA has the edge over CRI on leverage, with a lower net debt burden relative to earnings.
CRI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 48.5 | Neutral |
| Stochastic | 29.2 | Neutral |
CRI's weekly RSI is 49 (neutral) and its Stochastic is 29 (neutral).
TSLA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 54.3 | Neutral |
| Stochastic | 72.6 | Neutral |
TSLA's weekly RSI is 54 (neutral) and its Stochastic is 73 (neutral).
CRI PE vs Consumer Cyclical Sector
| Metric | CRI | Sector median | Relative |
|---|---|---|---|
| PE | 5.6x | 18x | 69% below |
| PE % | 1 | 47 | 46 pts below |
CRI has the edge over TSLA on valuation relative to its sector.
TSLA PE vs Consumer Cyclical Sector
| Metric | TSLA | Sector median | Relative |
|---|---|---|---|
| PE | 437x | 18x | 2,324% above |
| PE % | 84 | 47 | 37 pts above |
TSLA is trading at 437x earnings, a 2324% premium to the Consumer Cyclical sector's median of 18x.
CRI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $32.1 | 5.5% above |
| 20 week MA | $34.7 | 2.5% below |
| 50 week MA | $35.7 | 5% below |
| 100 week MA | $36.0 | 6% below |
| 200 week MA | $52.7 | 36% below |
CRI has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 36% below its 200-week average.
TSLA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $376.0 | 5.7% above |
| 20 week MA | $364.0 | 9.2% above |
| 50 week MA | $393.6 | 1% above |
| 100 week MA | $372.1 | 6.8% above |
| 200 week MA | $296.9 | 34% above |
TSLA has the edge over CRI on trend strength, trading above more of its moving averages.
CRI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $110.1 | $95.0 | -14% |
| 2021 | $95.0 | $98.7 | +3.9% |
| 2022 | $98.7 | $73.4 | -26% |
| 2023 | $73.4 | $74.9 | +2.1% |
| 2024 | $74.9 | $54.4 | -27% |
| 2025 | $54.4 | $31.7 | -42% |
| 2026 YTD | $31.7 | $33.9 | +6.9% |
CRI has the edge over TSLA on returns for 2026, with the stronger performance.
TSLA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $28.7 | $220.6 | +669% |
| 2021 | $220.6 | $355.7 | +61% |
| 2022 | $355.7 | $123.2 | -65% |
| 2023 | $123.2 | $248.5 | +102% |
| 2024 | $248.5 | $431.7 | +74% |
| 2025 | $431.7 | $475.2 | +10% |
| 2026 YTD | $475.2 | $397.5 | -16% |
TSLA's yearly returns have swung widely, from +669% in 2020 to −65% in 2022. It's down 16% so far in 2026.